CN102432055B - Lanthanum carbonate nano-particles for treating hyperphosphatemia, preparation method and use thereof - Google Patents
Lanthanum carbonate nano-particles for treating hyperphosphatemia, preparation method and use thereof Download PDFInfo
- Publication number
- CN102432055B CN102432055B CN 201110287007 CN201110287007A CN102432055B CN 102432055 B CN102432055 B CN 102432055B CN 201110287007 CN201110287007 CN 201110287007 CN 201110287007 A CN201110287007 A CN 201110287007A CN 102432055 B CN102432055 B CN 102432055B
- Authority
- CN
- China
- Prior art keywords
- lanthanum carbonate
- lanthanum
- preparation
- solution
- sodium bicarbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910017569 La2(CO3)3 Inorganic materials 0.000 title claims abstract description 102
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 title claims abstract description 101
- 229960001633 lanthanum carbonate Drugs 0.000 title claims abstract description 101
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 21
- 201000005991 hyperphosphatemia Diseases 0.000 title claims abstract description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 62
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 31
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 31
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 claims abstract description 28
- GAYSPCNXZCAPHX-UHFFFAOYSA-H lanthanum(3+);tricarbonate;octahydrate Chemical compound O.O.O.O.O.O.O.O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GAYSPCNXZCAPHX-UHFFFAOYSA-H 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 18
- 238000000498 ball milling Methods 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 56
- 238000006243 chemical reaction Methods 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000007864 aqueous solution Substances 0.000 claims description 27
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000012065 filter cake Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 229910009112 xH2O Inorganic materials 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 19
- 239000010452 phosphate Substances 0.000 description 19
- 238000002329 infrared spectrum Methods 0.000 description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 7
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- 229910052746 lanthanum Inorganic materials 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- WYWFMUBFNXLFJK-UHFFFAOYSA-N [Mo].[Sb] Chemical compound [Mo].[Sb] WYWFMUBFNXLFJK-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- KQROHCSYOGBQGJ-UHFFFAOYSA-N 5-Hydroxytryptophol Chemical compound C1=C(O)C=C2C(CCO)=CNC2=C1 KQROHCSYOGBQGJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- -1 lanthanum chloride Sodium bicarbonate Chemical compound 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229910002249 LaCl3 Inorganic materials 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 208000036696 Microcytic anaemia Diseases 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940118662 aluminum carbonate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- NKCVNYJQLIWBHK-UHFFFAOYSA-N carbonodiperoxoic acid Chemical compound OOC(=O)OO NKCVNYJQLIWBHK-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002603 lanthanum Chemical class 0.000 description 1
- CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 description 1
- LQFNMFDUAPEJRY-UHFFFAOYSA-K lanthanum(3+);phosphate Chemical compound [La+3].[O-]P([O-])([O-])=O LQFNMFDUAPEJRY-UHFFFAOYSA-K 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- KEQHHFKPFQFWAJ-UHFFFAOYSA-M lithium;acetate;hydrate Chemical compound [Li+].O.CC([O-])=O KEQHHFKPFQFWAJ-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000002037 soft tissue calcification Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域 technical field
本发明涉及一种用于治疗高磷血症的碳酸镧纳米颗粒的制备方法,以及由此制备方法获得的八水合碳酸镧La2(CO3)3·8H2O、含有1~4个水的碳酸镧La2(CO3)3·xH2O(其中x在1-4之间)和碳酸镧纳米颗粒,以及该碳酸镧纳米颗粒在制备用于治疗高磷血症的应用。The present invention relates to a preparation method of lanthanum carbonate nanoparticles for treating hyperphosphatemia, and lanthanum carbonate octahydrate La 2 (CO 3 ) 3 8H 2 O obtained by the preparation method, containing 1 to 4 water Lanthanum carbonate La 2 (CO 3 ) 3 ·xH 2 O (wherein x is between 1-4) and lanthanum carbonate nanoparticle, and the application of the lanthanum carbonate nanoparticle in preparation for treating hyperphosphatemia.
背景技术 Background technique
慢性肾病是全世界普遍的公共健康问题,它的一种主要并发症是由于肾脏不能排泄体内的磷酸盐,导致血液中磷酸盐水平升高而造成的高磷酸盐血症。Chronic kidney disease is a common public health problem all over the world. One of its main complications is hyperphosphatemia caused by the inability of the kidneys to excrete phosphate in the body, resulting in elevated phosphate levels in the blood.
高磷酸盐血症的症状主要是血液内磷酸盐含量超过正常水平,并可能会与继发甲状旁腺亢进,代谢性骨骼疾病,软组织钙化,心血管钙化有关。The symptoms of hyperphosphatemia are mainly blood phosphate levels that exceed normal levels, and may be related to secondary hyperparathyroidism, metabolic bone disease, soft tissue calcification, and cardiovascular calcification.
目前高磷血症的治疗主要有饮食上控制磷的摄入、透析法除磷、磷结合剂的应用以及必要时甲状旁腺的切除。但有90%~95%的终末期肾病患者是使用服用磷结合剂来减少肠道对磷的吸收而治疗高磷血症的。At present, the treatment of hyperphosphatemia mainly includes dietary control of phosphorus intake, phosphorus removal by dialysis, application of phosphorus binders, and removal of parathyroid glands when necessary. However, 90% to 95% of patients with end-stage renal disease treat hyperphosphatemia by taking phosphorus binders to reduce intestinal absorption of phosphorus.
磷结合剂主要分为传统的含铝或含钙的磷结合剂和非铝、非钙的磷结合剂两大种。含铝的磷结合剂如氢氧化铝、碳酸铝等,若长期服用会造成铝中毒,引起小细胞性贫血、骨软化、阿茨海默氏症等。而含钙的磷结合剂如碳酸钙、醋酸钙等,若长期使用会增加肠道内钙的吸收造成高钙血症,引起心脏和血管钙化。因此理想的治疗高磷血症的结合剂应该是非铝、非钙类的。碳酸镧就是其中一种。Phosphorus binders are mainly divided into two types: traditional aluminum or calcium-containing phosphorus binders and non-aluminum, non-calcium phosphorus binders. Aluminum-containing phosphorus binders such as aluminum hydroxide, aluminum carbonate, etc., if taken for a long time, will cause aluminum poisoning, causing microcytic anemia, osteomalacia, Alzheimer's disease, etc. And calcium-containing phosphorus binders such as calcium carbonate, calcium acetate, etc., if used for a long time, will increase the absorption of calcium in the intestine and cause hypercalcemia, causing heart and blood vessel calcification. Therefore, the ideal binder for the treatment of hyperphosphatemia should be non-aluminum and non-calcium. Lanthanum carbonate is one of them.
镧是一种对氧供体原子有强亲和力的稀土元素,镧盐能与食物中磷酸盐结合,形成磷酸镧复合物,通过阻碍磷酸盐的吸收,从而降低血液中磷酸盐的含量。碳酸镧(LC)是目前较为成熟的非铝、非钙类磷酸盐结合剂之一,它在胃肠道几无吸收,在体内组织中积聚也很少,不会导致血管钙化和其它副作用,耐受性也较好,它必将会成为治疗高磷血症的新药物。美国FDA已于2004年10月批准碳酸镧用于临床。到目前为止,已有多项用碳酸镧治疗高磷血症的报导。Lanthanum is a rare earth element with a strong affinity for oxygen donor atoms. Lanthanum salts can combine with phosphate in food to form a lanthanum phosphate complex, which can reduce the level of phosphate in the blood by hindering the absorption of phosphate. Lanthanum carbonate (LC) is currently one of the relatively mature non-aluminum and non-calcium phosphate binders. It has little absorption in the gastrointestinal tract and little accumulation in tissues in the body. It will not cause vascular calcification and other side effects. The tolerance is also good, and it will surely become a new drug for the treatment of hyperphosphatemia. The US FDA approved lanthanum carbonate for clinical use in October 2004. So far, there have been many reports on the treatment of hyperphosphatemia with lanthanum carbonate.
但镧离子是硬路易斯酸,有很强的与氢氧根结合的能力,在制备碳酸镧时如不注意条件,很容易生成碱式碳酸镧。到目前为止,碱式碳酸盐未被美国FDA批准可以用于治疗高磷血症,将其用于人体的安全性也未被证实。为了高磷血症患者的健康,安全,需要研发出在制备碳酸镧的过程中避免生成碳碱式碳酸镧的可靠方法。However, lanthanum ion is a hard Lewis acid, which has a strong ability to combine with hydroxide. If you do not pay attention to the conditions when preparing lanthanum carbonate, it is easy to generate basic lanthanum carbonate. So far, basic carbonate has not been approved by the US FDA to treat hyperphosphatemia, and its safety in humans has not been confirmed. For the health and safety of patients with hyperphosphatemia, it is necessary to develop a reliable method for avoiding the generation of lanthanum carbonate in the process of preparing lanthanum carbonate.
现有技术中关于碳酸镧的制备方法一般都是用碳酸钠作为原料来制备。例如有人在专利中报导了用Na2CO3与LaCl3反应,制备碳酸镧的方法,但重复该方法发现,生成的碳酸镧沉淀中夹杂一定量的La(OH)CO3。此外,现有方法生产的碳酸镧样品颗粒较大,大部分为3~4μm,颗粒较大会导致表面积相对较小,则吸收和吸附磷酸盐的效果不佳。The preparation method about lanthanum carbonate in the prior art generally all uses sodium carbonate as raw material to prepare. For example, someone reported in a patent the method of preparing lanthanum carbonate by reacting Na 2 CO 3 with LaCl 3 , but repeating this method found that a certain amount of La(OH)CO 3 was mixed in the generated lanthanum carbonate precipitate. In addition, the lanthanum carbonate sample produced by the existing method has relatively large particles, most of which are 3-4 μm. Large particles will result in a relatively small surface area, and the effect of absorbing and adsorbing phosphate is not good.
发明内容 Contents of the invention
本发明的目的之一就是为了寻找一种能够避免碱式碳酸镧生成的制备碳酸镧的方法,对所述碳酸镧进一步处理后能够更好地用于治疗高磷血症。One of the purposes of the present invention is to find a method for preparing lanthanum carbonate that can avoid the formation of basic lanthanum carbonate, and the lanthanum carbonate can be better used for treating hyperphosphatemia after further treatment.
我们注意到,Na2CO3水溶液呈碱性,在反应过程中溶液的pH值若不加以控制,很容易升高,导致生成的沉淀中夹杂La(OH)CO3。本发明人经研究发现,如果使用NaHCO3与LaCl3作为原料来制备碳酸镧,在制备过程中,会发生以下两个平行反应:We noticed that the Na 2 CO 3 aqueous solution is alkaline, and the pH value of the solution is easy to rise if not controlled during the reaction process, resulting in inclusion of La(OH)CO 3 in the formed precipitate. The inventor has found through research that if NaHCO3 and LaCl3 are used as raw materials to prepare lanthanum carbonate, in the preparation process, the following two parallel reactions will take place:
(1)NaHCO3与LaCl3反应释放出H+,(1) NaHCO 3 reacts with LaCl 3 to release H + ,
(2)H+会与HCO3 -反应,生成水和CO2。(2) H + will react with HCO 3 - to generate water and CO 2 .
这两个反应在制备碳酸镧过程中呈动态平衡,可以使反应在较低的pH下进行,从而在制备碳酸镧的同时,又能够避免碱式碳酸镧的生成。These two reactions are in dynamic equilibrium during the preparation of lanthanum carbonate, and the reaction can be carried out at a lower pH, thereby avoiding the generation of basic lanthanum carbonate while preparing lanthanum carbonate.
本发明人研究还发现,对于直接法制备的颗粒较大的碳酸镧样品,如果采用球磨的方法对样品进行研磨,就可以使样品颗粒更小,甚至达到纳米级别,其表面积显著增大,从而能够更好地吸收和吸附磷酸盐,因此在用于治疗高磷血症的药物中表现出良好的治疗效果。The inventor's research has also found that for the larger lanthanum carbonate sample prepared by the direct method, if the sample is ground by ball milling, the sample particle can be made smaller, even reaching the nanometer level, and its surface area is significantly increased. Capable of better absorption and adsorption of phosphate, thus exhibiting good therapeutic effect in drugs for the treatment of hyperphosphatemia.
因此,本发明提供一种用于治疗高磷血症的碳酸镧纳米颗粒的制备方法,包括以下步骤:Therefore, the present invention provides a kind of preparation method that is used for the treatment of the lanthanum carbonate nanoparticle of hyperphosphatemia, comprises the following steps:
步骤1),把碳酸氢钠溶液加入氯化镧溶液中,制备八水合碳酸镧,La2(CO3)3·8H2O,其红外光谱特征峰主要在850.3cm-1、746.6cm-1和678.6cm-1,另外在1477.9cm-1和1377.7cm-1处也有特征峰;所述氯化镧溶液的La3+浓度为0.5-5mol/L;Step 1), adding sodium bicarbonate solution into lanthanum chloride solution to prepare lanthanum carbonate octahydrate, La 2 (CO 3 ) 3 8H 2 O, the characteristic peaks of its infrared spectrum are mainly at 850.3cm -1 and 746.6cm -1 and 678.6cm -1 , and there are also characteristic peaks at 1477.9cm -1 and 1377.7cm -1 ; the La 3+ concentration of the lanthanum chloride solution is 0.5-5mol/L;
步骤2),然后在常压,40~120℃,优选50~100℃,更优选60~80℃温度的条件下脱水制备出稳定的含有1~4个水的碳酸镧,La2(CO3)3·xH2O,其中x在1-4之间,其红外光谱特征峰主要在849.6cm-1、747.4cm-1和681.0cm-1;另外在1483.4cm-1和1394.9cm-1处也有特征峰。Step 2), then dehydration at normal pressure, 40-120°C, preferably 50-100°C, more preferably 60-80°C, to prepare stable lanthanum carbonate containing 1-4 water, La 2 (CO 3 ) 3 ·xH 2 O, where x is between 1-4, the characteristic peaks of its infrared spectrum are mainly at 849.6cm -1 , 747.4cm -1 and 681.0cm -1 ; in addition at 1483.4cm -1 and 1394.9cm -1 There are also characteristic peaks.
步骤3),最后通过球磨的方法,把含有1~4个水的碳酸镧从微米颗粒球磨成纳米颗粒,其粒径为100~400nm。Step 3), finally by ball milling, the lanthanum carbonate containing 1-4 water is ball-milled from micron particles into nanoparticles, the particle size of which is 100-400nm.
以下详细描述本发明。The present invention is described in detail below.
在步骤1)中,生成八水合碳酸镧的方程式如下:In step 1), the equation that generates lanthanum carbonate octahydrate is as follows:
H++HCO-=H2O+CO2↑H + +HCO - =H 2 O+CO 2 ↑
2La3++3HCO3 -=La2(CO3)3↓+3H+ 2La 3+ +3HCO 3 - =La 2 (CO 3 ) 3 ↓+3H +
2La3++6HCO3 -=La2(CO3)3↓+3H2O+3CO2↑2La 3+ +6HCO 3 - =La 2 (CO 3 ) 3 ↓+3H 2 O+3CO 2 ↑
从方程式可以看出,溶液中存在两个反应,一个是La3+与HCO3 -反应生成La2(CO3)3沉淀,另一个是HCO3 -与溶液中的H+发生酸碱中和反应。上述两个平行反应酸碱中和反应,反应速度很快;另一个沉淀生成反应,在反应体系不存在碳酸镧晶核的条件下,反应几乎不进行。当滴加碳酸氢钠速度较慢时,由于没有碳酸镧晶核生成,沉淀反应不进行,因此所加入的碳酸氢钠只参与酸碱中和反应,使得溶液的pH在反应的初始阶段能升到5.5左右而未见碳酸镧沉淀的生成(见图1)。在这种情况下由于体系的pH值较高,制备的碳酸镧产物中夹杂碱式碳酸镧的风险较大。因此为了避免上述风险,我们采取下述措施:It can be seen from the equation that there are two reactions in the solution, one is the reaction of La 3+ and HCO 3 - to form La 2 (CO 3 ) 3 precipitation, and the other is the acid-base neutralization of HCO 3 - and H + in the solution reaction. The above two parallel reactions, the acid-base neutralization reaction, have a very fast reaction rate; the other precipitation formation reaction, under the condition that there is no lanthanum carbonate crystal nucleus in the reaction system, the reaction hardly proceeds. When the speed of adding sodium bicarbonate is slow, because there is no lanthanum carbonate crystal nucleus to generate, the precipitation reaction does not proceed, so the added sodium bicarbonate only participates in the acid-base neutralization reaction, so that the pH of the solution can rise in the initial stage of the reaction. To about 5.5 without the formation of lanthanum carbonate precipitate (see Figure 1). In this case, due to the higher pH value of the system, the risk of inclusion of basic lanthanum carbonate in the prepared lanthanum carbonate product is greater. Therefore, in order to avoid the above risks, we take the following measures:
根据本发明,步骤1)中,先向反应器中加入氯化镧水溶液,其La3+浓度为0.5-5mol/L,优选1-3mol/L,更优选2mol/L,pH为0-3。According to the present invention, in step 1), first add lanthanum chloride aqueous solution in the reactor, its La concentration is 0.5-5mol /L, preferably 1-3mol/L, more preferably 2mol/L, pH is 0-3 .
其中,步骤1)中,碳酸氢钠水溶液的加入分两个阶段:Wherein, in step 1), the addition of aqueous sodium bicarbonate solution is divided into two stages:
在开始阶段,先快速一次往氯化镧水溶液中加入少量碳酸氢钠水溶液,其浓度为0.2-4mol/L,优选0.3-3mol/L,更优选1mol/L,碳酸氢钠水溶液占氯化镧水溶液体积的0.05-0.4,优选0.1-0.3,更优选0.15-0.25,最优选0.2。In the initial stage, first quickly add a small amount of sodium bicarbonate aqueous solution to the aqueous lanthanum chloride solution at a time, the concentration of which is 0.2-4mol/L, preferably 0.3-3mol/L, more preferably 1mol/L, and the aqueous sodium bicarbonate solution accounts for The volume of the aqueous solution is 0.05-0.4, preferably 0.1-0.3, more preferably 0.15-0.25, most preferably 0.2.
在此情况下,当快速一次加入少量碳酸氢钠溶液后,溶液的pH值有一个升到3左右的突越,同时出现絮状的La2(CO3)3沉淀。这是由于一部分NaHCO3中和了体系的H+,使溶液的pH值升高,另一方面脉冲式的NaHCO3加入会造成反应体系中局部NaHCO3浓度较高,促进HCO3 -与La3+反应生成碳酸镧晶核。In this case, when a small amount of sodium bicarbonate solution was quickly added at one time, the pH value of the solution rose to about 3, and flocculent La 2 (CO 3 ) 3 precipitates appeared at the same time. This is because a part of NaHCO 3 neutralizes the H + in the system, which increases the pH value of the solution. On the other hand, the addition of pulsed NaHCO 3 will cause a higher local concentration of NaHCO 3 in the reaction system, which will promote HCO 3 - and La 3 + reaction to generate lanthanum carbonate nuclei.
然后,再以0.01mL/s-10mL/s,优选0.05mL/s-5mL/s,更优选0.08mL/s-2mL/s,最优选0.1mL/s-1mL/s的速度往氯化镧溶液中加入碳酸氢钠溶液,直至pH值出现拐点时反应停止。Then, with 0.01mL/s-10mL/s, preferably 0.05mL/s-5mL/s, more preferably 0.08mL/s-2mL/s, most preferably 0.1mL/s-1mL/s speed to lanthanum chloride Sodium bicarbonate solution was added in the solution until the reaction stopped when the inflection point appeared in the pH value.
在此过程中,进一步加入HCO3 -后反应体系的pH值降低,这主要是因为HCO3 -与La3+反应生成La2(CO3)3、释放大量H+所致。随着碳酸氢钠的进一步加入,溶液反应体系中所产生的La2(CO3)3数量不断增加,但体系的pH值基本保持不变,这是由于酸碱中和反应和沉淀反应达到一个动态平衡所致,因此整个La2(CO3)3生成反应是在一个较低的pH条件下(如4左右)进行。当体系中的La3+被完全转化成La2(CO3)3沉淀后,随着NaHCO3进一步加入,体系的pH成突跃性升高,因此我们可以通过最后这个突跃来判断反应的终点。During this process, the pH value of the reaction system decreased after further adding HCO 3 - , which was mainly due to the reaction of HCO 3 - and La 3+ to generate La 2 (CO 3 ) 3 and release a large amount of H + . With the further addition of sodium bicarbonate, the amount of La 2 (CO 3 ) 3 produced in the solution reaction system increases continuously, but the pH value of the system remains basically unchanged, which is due to the acid-base neutralization reaction and precipitation reaction reaching a Due to dynamic equilibrium, the entire La 2 (CO 3 ) 3 generation reaction is carried out at a lower pH (such as around 4). When the La 3+ in the system is completely converted into La 2 (CO 3 ) 3 precipitation, with the further addition of NaHCO 3 , the pH of the system rises abruptly, so we can judge the reaction by the last jump. end.
根据本发明,步骤1)中,反应停止后,将滤液抽滤,并用蒸馏水洗涤三次,将八水合碳酸镧滤饼放在通风处自然晾干。经红外光谱鉴定,该八水合碳酸镧的红外光谱特征峰主要在850.3cm-1、746.6cm-1和678.6cm-1,另外在1477.9cm-1和1377.7cm-1处也有特征峰。According to the present invention, in step 1), after the reaction stops, the filtrate is sucked and washed three times with distilled water, and the octahydrate lanthanum carbonate filter cake is placed in a ventilated place to dry naturally. According to infrared spectrum identification, the infrared spectrum characteristic peaks of the octahydrate lanthanum carbonate are mainly at 850.3cm -1 , 746.6cm -1 and 678.6cm -1 , and there are also characteristic peaks at 1477.9cm -1 and 1377.7cm -1 .
在步骤2)中,为了使步骤1)形成的八水合碳酸镧脱水,根据本发明,将八水合碳酸镧放在烘箱中,在常压下,在温度为40~120℃,优选50~100℃,更优选60~80℃下保持18~24h,即可得到更加稳定的1~4个水的碳酸镧,La2(CO3)3·xH2O,其中x在1-4之间,优选x为1.5-3.5,更优选x为2.5-3.4,最优选x为3.3。In step 2), in order to dehydrate the eight-hydrated lanthanum carbonate formed in step 1), according to the present invention, octahydrated lanthanum carbonate is placed in an oven under normal pressure at a temperature of 40 to 120° C., preferably 50 to 100 °C, more preferably at 60-80 °C for 18-24 hours, you can get a more stable lanthanum carbonate with 1-4 water, La 2 (CO 3 ) 3 ·xH 2 O, where x is between 1-4, Preferably x is 1.5-3.5, more preferably x is 2.5-3.4, most preferably x is 3.3.
经红外光谱鉴定,该1~4个水的碳酸镧的红外光谱特征峰主要在849.6cm-1、747.4cm-1和681.0cm-1;另外在1483.4cm-1和1394.9cm-1处也有特征峰。According to the infrared spectrum identification, the characteristic peaks of the infrared spectrum of the lanthanum carbonate of the 1 to 4 waters are mainly at 849.6cm -1 , 747.4cm -1 and 681.0cm -1 ; there are also characteristic peaks at 1483.4cm -1 and 1394.9cm -1 peak.
在步骤3)中,为了制备纳米级碳酸镧,根据本发明,将步骤2)获得的含有1~4个水的碳酸镧放在球磨机中球磨1-5小时,优选1.5-3小时,最优选2小时,得到粒径为100~400nm,优选200~300nm的碳酸镧颗粒。In step 3), in order to prepare nano-scale lanthanum carbonate, according to the present invention, the lanthanum carbonate obtained in step 2) containing 1 to 4 water is placed in a ball mill for 1-5 hours, preferably 1.5-3 hours, most preferably After 2 hours, lanthanum carbonate particles with a particle size of 100-400 nm, preferably 200-300 nm, are obtained.
根据本发明的上述制备方法,在步骤3)中制得碳酸镧纳米颗粒,其粒径为100~400nm,优选为200~300nm。According to the above preparation method of the present invention, lanthanum carbonate nanoparticles are prepared in step 3), and the particle diameter thereof is 100-400 nm, preferably 200-300 nm.
根据本发明制得的碳酸镧纳米颗粒可以制备用于治疗高磷血症的药物。The lanthanum carbonate nanoparticles prepared according to the present invention can be used to prepare medicines for treating hyperphosphatemia.
本发明的创新之处主要体现在以下几个方面:The innovation of the present invention is mainly reflected in the following aspects:
1、为避免形成碱式碳酸镧,我们使用NaHCO3而不是Na2CO3。并且在反应开始时在低pH的LaCl3溶液中下先快速一次加入一定量的NaHCO3水溶液,使溶液局部pH过高而生成碳酸镧沉淀的晶核,然后再一滴滴往LaCl3溶液滴加NaHCO3水溶液,使新生成的碳酸镧沉淀在最初的晶核上外延生长。只有这样,体系中两个平行反应同步进行,从而使反应体系的pH值实现动态平衡,从而在较低的pH环境下制备碳酸镧。1. To avoid the formation of lanthanum subcarbonate, we use NaHCO 3 instead of Na 2 CO 3 . And at the beginning of the reaction, add a certain amount of NaHCO 3 aqueous solution quickly in the low pH LaCl 3 solution at one time, so that the local pH of the solution is too high to generate crystal nuclei of lanthanum carbonate precipitation, and then add drop by drop to the LaCl 3 solution NaHCO 3 aqueous solution, so that the newly formed lanthanum carbonate precipitates epitaxial growth on the initial nucleus. Only in this way, the two parallel reactions in the system are carried out synchronously, so that the pH value of the reaction system can achieve a dynamic balance, thereby preparing lanthanum carbonate in a lower pH environment.
2、我们全程监控溶液的pH值,绘制整个反应过程的pH-反应时间曲线,当体系中的镧离子完全转化为碳酸镧时,体系的pH会发生突跃。可以将该突跃作为判据,停止反应。利用反应过程的pH-反应时间曲线,可以实现碳酸镧的生产自动化。2. We monitor the pH value of the solution throughout the process, and draw the pH-reaction time curve of the entire reaction process. When the lanthanum ions in the system are completely converted into lanthanum carbonate, the pH of the system will suddenly jump. This jump can be used as a criterion to stop the reaction. Utilizing the pH-reaction time curve of the reaction process, the production automation of lanthanum carbonate can be realized.
3、直接法制备的碳酸镧样品颗粒较大,大部分为3~4μm,为了使样品颗粒更小表面积增大、更好吸收和吸附磷酸盐,采用球磨的方法对样品进行研磨,从而得到了粒径为100~400nm,优选200~300nm的颗粒。3. The lanthanum carbonate sample prepared by the direct method has relatively large particles, most of which are 3-4 μm. In order to make the sample particles smaller and increase the surface area, better absorb and adsorb phosphate, the sample is ground by ball milling, thus obtaining Particles with a particle diameter of 100 to 400 nm, preferably 200 to 300 nm.
附图说明 Description of drawings
图1:缓慢滴加NaHCO3过程中加入体积-pH变化曲线;Figure 1: Add volume-pH change curve in the process of slowly adding NaHCO 3 ;
图2:直接法制备八水合碳酸镧的时间-pH变化曲线;Figure 2: The time-pH curve for the preparation of lanthanum carbonate octahydrate by the direct method;
图3:直接法合成八水合碳酸镧与标准卡片(25-1400)比较;Fig. 3: Direct method synthesis octahydrate lanthanum carbonate compares with standard card (25-1400);
图4:八水合碳酸镧的红外光谱;Figure 4: Infrared spectrum of lanthanum carbonate octahydrate;
图5:含1~4个水的碳酸镧红外光谱;该图中的碳酸镧含3.3个水,其特征波数在低波段;Figure 5: Infrared spectrum of lanthanum carbonate containing 1 to 4 water; the lanthanum carbonate in this figure contains 3.3 water, and its characteristic wavenumber is in the low band;
图6:含水碳酸镧的SEM图;Figure 6: SEM image of hydrous lanthanum carbonate;
图7:球磨后获得的纳米颗粒碳酸镧的SEM图;Figure 7: SEM image of nanoparticle lanthanum carbonate obtained after ball milling;
图8:八水合碳酸镧的热重曲线;Figure 8: Thermogravimetric curve of lanthanum carbonate octahydrate;
图9:含1~4个水的碳酸镧的热重曲线;Fig. 9: the thermogravimetric curve of the lanthanum carbonate containing 1~4 water;
图10:磷酸盐的标准曲线;Figure 10: Standard curve for phosphate;
图11:pH3.0情况下的磷酸盐吸附曲线;Figure 11: Phosphate adsorption curve at pH 3.0;
图12:pH3.0情况下的磷酸盐吸附曲线;Figure 12: Phosphate adsorption curve at pH 3.0;
图13:pH5.4情况下的磷酸盐吸附曲线;Figure 13: Phosphate adsorption curve at pH 5.4;
图14:纳米颗粒的XRD图。Figure 14: XRD pattern of nanoparticles.
具体实施方式 Detailed ways
以下通过实施例来进一步描述本发明,但本发明并不限于这些实施方式。The present invention is further described by the following examples, but the present invention is not limited to these embodiments.
一、碳酸镧的表征实验1. Characterization experiment of lanthanum carbonate
1、XRD1. XRD
X射线多晶衍射仪(XRD,Rigaku Dmax-2000):CuK单色辐射源,加速电压40KV,电流150mV,用于测定样品的晶型及其变化、结晶度、结晶完善程度。扫描范围:5~60°,采用连续扫描方式。并与La2(CO3)3·8H2O标准卡片25-1400进行比较。X-ray polycrystal diffractometer (XRD, Rigaku Dmax-2000): CuK Monochromatic radiation source, accelerating voltage 40KV, current 150mV, used to determine the crystal form and its change, crystallinity and crystallization perfection of the sample. Scanning range: 5~60°, using continuous scanning mode. And compared with La 2 (CO 3 ) 3 ·8H 2 O standard card 25-1400.
2、滴定、元素分析2. Titration and elemental analysis
2.1实验采用EDTA滴定样品得到镧元素的含量2.1 The experiment uses EDTA to titrate the sample to obtain the content of lanthanum element
配制250mL 0.02mol/L锌标准溶液:Prepare 250mL 0.02mol/L zinc standard solution:
基准物氧化锌于1000℃马弗炉中干燥5h,降温至120℃后置于干燥器中,冷却至室温。称取0.8118g氧化锌,加入盐酸溶解,定容至250mL,配制浓度为1.995×10-2M的锌溶液The standard zinc oxide was dried in a muffle furnace at 1000°C for 5 hours, cooled to 120°C, placed in a desiccator, and cooled to room temperature. Weigh 0.8118g of zinc oxide, add hydrochloric acid to dissolve it, dilute to 250mL, and prepare a zinc solution with a concentration of 1.995×10 -2 M
配制EDTA溶液:Prepare EDTA solution:
称取EDTA 7.4464g,溶解到1000mL水中。Weigh 7.4464g of EDTA and dissolve it in 1000mL of water.
EDTA标定:EDTA calibration:
用移液管吸取20.00mL Zn2+标准溶液于锥形瓶中,加2滴二甲酚橙指示剂,滴加200g/L六亚甲基四胺至溶液呈现稳定紫红色,再加5mL六亚甲基四胺。用EDTA滴定,当溶液由紫红色恰转变为黄色即为终点。平行测三次。Use a pipette to draw 20.00mL Zn 2+ standard solution into the conical flask, add 2 drops of xylenol orange indicator, add 200g/L hexamethylenetetramine dropwise until the solution becomes stable purple, then add 5mL Methylenetetramine. Titrate with EDTA, when the solution changes from purple to yellow, it is the end point. Measured three times in parallel.
La3+含量的测定:Determination of La 3+ content:
称取一定量的样品,加盐酸完全溶解,定容至100.00mL,用移液管吸取15.00mL,滴定方法同EDTA标定。平行测三次。Weigh a certain amount of sample, add hydrochloric acid to dissolve it completely, set the volume to 100.00mL, draw 15.00mL with a pipette, and titrate with EDTA. Measured three times in parallel.
2.2元素分析2.2 Elemental analysis
使用vario EL元素分析仪(Elementar AnalysensystemeGmbH)对样品C和H的元素分析得到样品的含碳量和含氢量,同时可以通过H含量来计算样品还有多少个水。Using the vario EL elemental analyzer (Elementar Analysensysteme GmbH) to analyze the elements of samples C and H to obtain the carbon content and hydrogen content of the sample, and at the same time, the amount of water in the sample can be calculated through the H content.
3.红外光谱3. Infrared spectroscopy
使用Thermo Scientific公司NICOLET iN10 MX显微红外光谱仪;检测器:MCT/A;分束器:KBr/Ge;扫描次数:64;分辨率:4cm-1。NICOLET iN10 MX micro-infrared spectrometer from Thermo Scientific Company was used; detector: MCT/A; beam splitter: KBr/Ge; number of scans: 64; resolution: 4cm -1 .
4.SEM(扫描电镜)观察颗粒大小4. SEM (scanning electron microscope) to observe the particle size
使用JEOL公司生产的JSM-6700F型场发射扫描电子显微镜进行,加速电压为5kV。JSM-6700F Field Emission Scanning Electron Microscope produced by JEOL Company was used, and the accelerating voltage was 5kV.
5.热重表征5. Thermogravimetric Characterization
使用美国Thermal Analysis公司的Q600SDT TGA-DTA-DSC同步测定仪,扫描范围为10℃--1000℃,升温速度为10℃/min。The Q600SDT TGA-DTA-DSC synchronous analyzer from Thermal Analysis Company of the United States was used, the scanning range was 10°C--1000°C, and the heating rate was 10°C/min.
二、制备实施例Two, preparation embodiment
实施例1:Example 1:
先向烧瓶中加入50mL氯化镧水溶液,其La3+浓度为2mol/L,pH为0~2。开始时,先快速一次往氯化镧水溶液中加入10mL碳酸氢钠水溶液,其浓度为1mol/L,此时溶液的pH值有一个升到3左右的突越,同时出现絮状的La2(CO3)3沉淀。然后再以0.08mL/s的速度往氯化镧溶液中加入碳酸氢钠溶液,直至pH值出现拐点,呈突跃性升高时反应停止,共加入碳酸氢钠溶液320mL。图2给出直接法制备八水合碳酸镧时间-pH变化曲线。First add 50 mL of lanthanum chloride aqueous solution into the flask, its La 3+ concentration is 2 mol/L, and its pH is 0-2. At the beginning, first quickly add 10 mL of sodium bicarbonate aqueous solution to the lanthanum chloride aqueous solution at one time, and its concentration is 1mol/L. At this time, the pH value of the solution has a sudden rise to about 3, and flocculent La 2 ( CO 3 ) 3 precipitates. Then add sodium bicarbonate solution to the lanthanum chloride solution at a speed of 0.08mL/s until the pH value shows an inflection point, and the reaction stops when the pH value rises abruptly, and a total of 320mL of sodium bicarbonate solution is added. Figure 2 shows the time-pH curve for the preparation of lanthanum carbonate octahydrate by the direct method.
滤液抽滤,并用蒸馏水洗涤三次,将滤饼放在通风处自然晾干。The filtrate was suction filtered, washed three times with distilled water, and the filter cake was placed in a ventilated place to dry naturally.
图3给出了所获得的八水合碳酸镧(标记为03-25)与标准卡片(25-1400)比较。可以看出峰位基本一致,和标准卡片的匹配度约为920(100%匹配时数值为1000)。Figure 3 shows the obtained lanthanum carbonate octahydrate (labeled 03-25) compared with the standard card (25-1400). It can be seen that the peak positions are basically the same, and the matching degree with the standard card is about 920 (the value is 1000 for 100% matching).
将获得的八水合碳酸镧放在烘箱中,在常压下,在一定温度下保持18h,得到含1~4个水的碳酸镧,具体而言,当此温度为55℃时,得到含3.3个水的碳酸镧,当此温度为75℃时,得到含2.5个水的碳酸镧,此温度为120℃时,得到含1个水的碳酸镧。Put the obtained lanthanum carbonate octahydrate in an oven, keep it at a certain temperature under normal pressure for 18 hours, and obtain lanthanum carbonate containing 1 to 4 water, specifically, when the temperature is 55°C, you can get lanthanum carbonate containing 3.3 The lanthanum carbonate of water, when this temperature is 75 ℃, obtains the lanthanum carbonate that contains 2.5 waters, and when this temperature is 120 ℃, obtains the lanthanum carbonate that contains 1 water.
将制得的含1~4个水的碳酸镧放在球磨机中,球磨2小时,得到200~300nm的碳酸镧颗粒。The prepared lanthanum carbonate containing 1 to 4 water is placed in a ball mill and ball milled for 2 hours to obtain lanthanum carbonate particles with a size of 200 to 300 nm.
表1表示EDTA滴定La2(CO3)3·8H2O中La含量结果。Table 1 shows the results of EDTA titration of La content in La 2 (CO 3 ) 3 ·8H 2 O.
表1Table 1
表3为八水合碳酸镧干燥脱水前后的元素分析结果。Table 3 shows the elemental analysis results of lanthanum carbonate octahydrate before and after drying and dehydration.
表3table 3
表4为样品干燥前后的C与La含量变化。Table 4 shows the changes in C and La content of the samples before and after drying.
表4Table 4
可见,基本没有碱式碳酸镧的存在。It can be seen that there is basically no lanthanum carbonate subsistence.
图4为八水合碳酸镧的红外光谱,Fig. 4 is the infrared spectrum of octahydrate lanthanum carbonate,
图5是是含1~4个水的碳酸镧的红外光谱。Fig. 5 is the infrared spectrum of lanthanum carbonate containing 1 to 4 waters.
可见,在较低波数时,八水合碳酸镧的特征峰分别在850,746,678cm-1,而碱式碳酸镧的特征峰在858,724,696cm-1;因此红外光谱表明,该实施例获得的产物是碳酸镧而非碱式碳酸镧。It can be seen that, at lower wavenumbers, the characteristic peaks of lanthanum carbonate octahydrate are respectively at 850, 746, and 678cm -1 , while the characteristic peaks of lanthanum carbonate basic are at 858,724, and 696cm -1 ; The product obtained was lanthanum carbonate rather than lanthanum hydroxycarbonate.
图6是含水碳酸镧的SEM图;Fig. 6 is the SEM figure of hydrous lanthanum carbonate;
图7是球磨后获得的纳米颗粒碳酸镧的SEM。Figure 7 is the SEM of the nanoparticle lanthanum carbonate obtained after ball milling.
从图6中看出,样品为片状结构,颗粒大小为3~4μm;It can be seen from Figure 6 that the sample is a sheet-like structure with a particle size of 3-4 μm;
从图7看出,进行球磨后得到纳米级的颗粒,样品颗粒变为200~300nm。It can be seen from Fig. 7 that nanoscale particles are obtained after ball milling, and the sample particles become 200-300nm.
图8为八水合碳酸镧的热重曲线;Fig. 8 is the thermogravimetric curve of octahydrate lanthanum carbonate;
图9为含1~4个水的碳酸镧的热重曲线。Fig. 9 is the thermogravimetric curve of lanthanum carbonate containing 1 to 4 waters.
实施例2:Example 2:
先向烧瓶中加入50mL氯化镧水溶液,其La3+浓度为2.5mol/L,pH为1.5。开始时,先快速一次往氯化镧水溶液中加入15mL碳酸氢钠水溶液,其浓度为0.81mol/L,此时溶液的pH值有一个升到3左右的突越,同时出现絮状的La2(CO3)3沉淀。然后再以2mL/s的速度往氯化镧溶液中加入碳酸氢钠溶液,直至pH值出现拐点,呈突跃性升高时反应停止,共加入碳酸氢钠溶液380mL。滤液抽滤,并用蒸馏水洗涤三次,将滤饼放在通风处自然晾干。First add 50 mL of lanthanum chloride aqueous solution to the flask, the La 3+ concentration is 2.5 mol/L, and the pH is 1.5. At the beginning, add 15mL sodium bicarbonate aqueous solution to the lanthanum chloride aqueous solution at one time quickly, and its concentration is 0.81mol/L . (CO 3 ) 3 precipitates. Then add sodium bicarbonate solution to the lanthanum chloride solution at a rate of 2 mL/s until the pH value shows an inflection point, and the reaction stops when the pH value rises abruptly, and a total of 380 mL of sodium bicarbonate solution is added. The filtrate was suction filtered, washed three times with distilled water, and the filter cake was placed in a ventilated place to dry naturally.
图3给出了所获得的八水合碳酸镧(标记为02-23)与标准卡片(25-1400)比较。可以看出峰位基本一致,和标准卡片的匹配度约为920。Figure 3 shows the obtained lanthanum carbonate octahydrate (labeled 02-23) compared with the standard card (25-1400). It can be seen that the peak positions are basically the same, and the matching degree with the standard card is about 920.
将获得的八水合碳酸镧放在烘箱中,在常压下,在一定温度下保持24h,得到1~4个水的碳酸镧,具体而言,当此温度为60℃时,得到含3.0个水的碳酸镧,当此温度为75℃时,得到含2.4个水的碳酸镧,此温度为110℃时,得到含1.5个水的碳酸镧。Put the obtained lanthanum carbonate octahydrate in an oven, keep it at a certain temperature under normal pressure for 24 hours, and obtain lanthanum carbonate with 1 to 4 hydrates. Specifically, when the temperature is 60°C, you can get The lanthanum carbonate of water, when this temperature is 75 ℃, obtains the lanthanum carbonate that contains 2.4 waters, and when this temperature is 110 ℃, obtains the lanthanum carbonate that contains 1.5 waters.
将制得的1~4个水的碳酸镧放在球磨机中,球磨3小时,得到200~300nm的碳酸镧颗粒。The prepared lanthanum carbonate of 1-4 water is placed in a ball mill and ball-milled for 3 hours to obtain lanthanum carbonate particles of 200-300 nm.
表2EDTA滴定La2(CO3)3·8H2O中La含量结果Table 2 EDTA titration results of La content in La 2 (CO 3 ) 3 ·8H 2 O
表2Table 2
实施例3:Example 3:
先向烧瓶中加入50mL氯化镧水溶液,其La3+浓度为1.5mol/L,pH为1.0。开始时,先快速一次往氯化镧水溶液中加入8mL碳酸氢钠水溶液,其浓度为1.51mol/L,此时溶液的pH值有一个升到3左右的突越,同时出现絮状的La2(CO3)3沉淀。然后再以1.5mL/s的速度往氯化镧溶液中加入碳酸氢钠溶液,直至pH值出现拐点,呈突跃性升高时反应停止,共加入碳酸氢钠溶液260mL。滤液抽滤,并用蒸馏水洗涤三次,将滤饼放在通风处自然晾干。First add 50 mL of lanthanum chloride aqueous solution to the flask, its La 3+ concentration is 1.5 mol/L, and its pH is 1.0. At the beginning, add 8 mL of sodium bicarbonate solution to the aqueous solution of lanthanum chloride quickly at one time, and its concentration is 1.51 mol/L . (CO 3 ) 3 precipitates. Then add sodium bicarbonate solution to the lanthanum chloride solution at a rate of 1.5 mL/s until the pH value shows an inflection point, and the reaction stops when the pH value rises abruptly, and 260 mL of sodium bicarbonate solution is added in total. The filtrate was suction filtered, washed three times with distilled water, and the filter cake was placed in a ventilated place to dry naturally.
将获得的八水合碳酸镧放在烘箱中,在常压下,在一定温度下保持20h,得到3~4个水的碳酸镧,具体而言,当此温度为50℃时,得到含3.5个水的碳酸镧,当此温度为80℃时,得到含2.0个水的碳酸镧,此温度为120℃时,得到含1个水的碳酸镧。Put the obtained lanthanum carbonate octahydrate in an oven, keep it at a certain temperature under normal pressure for 20 hours, and obtain lanthanum carbonate with 3 to 4 water, specifically, when the temperature is 50°C, you can get The lanthanum carbonate of water, when this temperature is 80 ℃, obtain the lanthanum carbonate that contains 2.0 water, when this temperature is 120 ℃, obtain the lanthanum carbonate that contains 1 water.
将制得的1~4个水的碳酸镧放在球磨机中,球磨1.5小时,得到200~300nm的碳酸镧颗粒。The prepared lanthanum carbonate with 1 to 4 water is placed in a ball mill and ball milled for 1.5 hours to obtain lanthanum carbonate particles with a size of 200 to 300 nm.
三、应用实施例3. Application Examples
磷酸盐结合实验:钼锑抗钼蓝光度法测定磷酸盐含量Phosphate Binding Assay: Molybdenum Antimony Antimolybdenum Blue Photometric Determination of Phosphate Content
磷酸盐标准曲线的绘制Drawing of phosphate standard curve
取7支50mL比色管,分别磷酸标准操作溶液0mL,0.50mL,1.00mL,3.00mL,5.00mL,10.00mL,15.00mL加入1mL抗坏血酸溶液,混匀。30s后加2mL钼酸盐溶液,充分混匀。放置15min,于700nm波长处,以试剂空白溶液为参比,测量吸光度,绘制标准曲线。Take 7 50mL colorimetric tubes, add 1mL ascorbic acid solution to the phosphoric acid standard operating solution 0mL, 0.50mL, 1.00mL, 3.00mL, 5.00mL, 10.00mL, 15.00mL respectively, and mix well. After 30s, add 2mL molybdate solution and mix well. Stand for 15 minutes, measure the absorbance at a wavelength of 700nm with the reagent blank solution as a reference, and draw a standard curve.
图10为磷酸盐标准曲线。Figure 10 is a phosphate standard curve.
pH2.0情况下的磷酸盐结合曲线Phosphate binding curve at pH 2.0
配制氨基乙酸-盐酸为2.0缓冲液,使用钼锑抗钼蓝紫外光度法测定溶液中的磷酸盐含量,确定碳酸镧结合率。Glycine-hydrochloric acid was prepared as 2.0 buffer solution, and the phosphate content in the solution was determined by molybdenum-antimony anti-molybdenum blue ultraviolet spectrophotometry to determine the binding rate of lanthanum carbonate.
图11为pH2.0磷酸盐结合曲线。Figure 11 is a pH 2.0 phosphate binding curve.
从图11可以看出反应在10min时出现拐点,80%的PO4 3-转化为LaPO4,然后并没有更多磷酸盐被结合。It can be seen from Fig. 11 that the reaction appeared an inflection point at 10 min, 80% of PO 4 3- was converted into LaPO 4 , and then no more phosphate was incorporated.
pH3.0情况下的磷酸盐结合曲线Phosphate binding curve at pH 3.0
配制醋酸-氢氧化锂为3.0缓冲液,使用钼锑抗钼蓝紫外光度法测定溶液中的磷酸盐含量,确定碳酸镧结合率。Prepare acetic acid-lithium hydroxide as 3.0 buffer solution, use molybdenum antimony antimolybdenum blue ultraviolet photometry to measure the phosphate content in the solution, and determine the binding rate of lanthanum carbonate.
图12为pH3.0磷酸盐结合曲线。Figure 12 is a pH 3.0 phosphate binding curve.
从图12可以看出反应在10min时出现拐点,55%的PO4 3-转化为LaPO4,然后反应速度减慢,经过4h溶液中PO4 3-的几乎100%被转化为LaPO4。It can be seen from Figure 12 that an inflection point appeared in the reaction at 10 minutes, 55% of PO 4 3- was converted into LaPO 4 , and then the reaction speed slowed down, and almost 100% of PO 4 3- in the solution was converted into LaPO 4 after 4 hours.
pH5.4情况下的磷酸盐结合曲线Phosphate binding curve at pH 5.4
配制六亚甲基四胺-HCl为pH5.4缓冲液,使用钼锑抗钼蓝紫外光度法测定溶液中的磷酸盐含量,确定碳酸镧结合率。Prepare hexamethylenetetramine-HCl as pH5.4 buffer solution, use molybdenum antimony antimolybdenum blue ultraviolet photometry to measure the phosphate content in the solution, and determine the binding rate of lanthanum carbonate.
图13为pH5.4磷酸盐结合曲线。Figure 13 is a pH 5.4 phosphate binding curve.
从图13中看出,在pH5.4的条件下,结合曲线并没有出现明显的拐点,经过4h,溶液中的磷酸盐基本已经被结合完全。It can be seen from Fig. 13 that under the condition of pH 5.4, the binding curve did not show an obvious inflection point, and after 4 hours, the phosphate in the solution was basically completely bound.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110287007 CN102432055B (en) | 2011-09-23 | 2011-09-23 | Lanthanum carbonate nano-particles for treating hyperphosphatemia, preparation method and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110287007 CN102432055B (en) | 2011-09-23 | 2011-09-23 | Lanthanum carbonate nano-particles for treating hyperphosphatemia, preparation method and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102432055A CN102432055A (en) | 2012-05-02 |
CN102432055B true CN102432055B (en) | 2013-10-16 |
Family
ID=45980465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110287007 Expired - Fee Related CN102432055B (en) | 2011-09-23 | 2011-09-23 | Lanthanum carbonate nano-particles for treating hyperphosphatemia, preparation method and use thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102432055B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2693176C1 (en) * | 2018-12-28 | 2019-07-01 | Общество С Ограниченной Ответственностью "Лаборатория Инновационных Технологий" | Method of producing carbonates of rare-earth elements |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016051609A1 (en) * | 2014-10-02 | 2016-04-07 | 東和薬品株式会社 | Drug comprising lanthanum carbonate hydrate having adjusted particle size |
CN104473963B (en) * | 2014-12-24 | 2017-10-10 | 厦门科明达科技有限公司 | The preparation method of rare earth chemistry medicine lanthanum carbonate chewable tablets |
CN107876000A (en) * | 2017-10-30 | 2018-04-06 | 浙江大学 | A kind of nanometer dephosphorization agent, preparation method and application |
WO2020085020A1 (en) * | 2018-10-26 | 2020-04-30 | 住友化学株式会社 | Method for producing lanthanum carbonate hydrate |
TR201901877A2 (en) * | 2019-02-07 | 2019-04-22 | Hacettepe Ueniversitesi | FORMULATIONS AND PREPARATION METHODS THAT INCREASE LANTHAN CARBONATE'S BIOACTIVITY |
CN113029978A (en) * | 2019-12-25 | 2021-06-25 | 远大生命科学(辽宁)有限公司 | Method for detecting phosphorus binding capacity of lanthanum-containing reagent |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1184428A (en) * | 1995-03-25 | 1998-06-10 | 约翰逊马西有限公司 | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
WO2010131255A1 (en) * | 2009-05-15 | 2010-11-18 | Natco Pharma Limited | Process for the preparation of lanthanum carbonate dihydrate |
-
2011
- 2011-09-23 CN CN 201110287007 patent/CN102432055B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1184428A (en) * | 1995-03-25 | 1998-06-10 | 约翰逊马西有限公司 | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
WO2010131255A1 (en) * | 2009-05-15 | 2010-11-18 | Natco Pharma Limited | Process for the preparation of lanthanum carbonate dihydrate |
Non-Patent Citations (2)
Title |
---|
P.Jeevanandam, et al..Synthesis of morphologically controlled lanthanum carbonate particles using ultrasound irradiation.《Journal of Materials Chemistry》.2001,第11卷第870页右栏第4行至第6行,图2(b). |
Synthesis of morphologically controlled lanthanum carbonate particles using ultrasound irradiation;P.Jeevanandam, et al.;《Journal of Materials Chemistry》;20010206;第11卷;第870页右栏第4行至第6行,图2(b) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2693176C1 (en) * | 2018-12-28 | 2019-07-01 | Общество С Ограниченной Ответственностью "Лаборатория Инновационных Технологий" | Method of producing carbonates of rare-earth elements |
Also Published As
Publication number | Publication date |
---|---|
CN102432055A (en) | 2012-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102432055B (en) | Lanthanum carbonate nano-particles for treating hyperphosphatemia, preparation method and use thereof | |
CN102442692B (en) | Preparation method of lanthanum carbonate hydrate | |
Yasaei et al. | Synthesis and characterization of ZnAl-NO3 (-CO3) layered double hydroxide: A novel structure for intercalation and release of simvastatin | |
Gao et al. | Intercalation and controlled release properties of vitamin C intercalated layered double hydroxide | |
US9314481B2 (en) | Method | |
US20120288535A1 (en) | Rare earth nanoparticles | |
JP5910887B2 (en) | Water-swellable layered double hydroxide and production method thereof, gel-like or sol-like substance, double hydroxide nanosheet and production method thereof | |
KR101514470B1 (en) | Ligand-modified polyoxo-hydroxy metal ion materials, their uses and methods for their preparation | |
KR101653423B1 (en) | Phosphate binding materials and their uses | |
US20230114986A1 (en) | Light-emitting nanoparticles, cell detection method using same, animal treatment method, medical device, cell visualization method, and method for reducing injury to cell | |
UA115134C2 (en) | Mesoporous titanium dioxide nanoparticles and process for their production | |
Safronikhin et al. | Double-jet precipitation synthesis of CaF2 nanoparticles: The effect of temperature, solvent, and stabilizer on size and morphology | |
Podbršček et al. | The preparation of zinc silicate/ZnO particles and their use as an efficient UV absorber | |
Jerdioui et al. | Effects of gallic acid on the nanocrystalline hydroxyapatite formation using the neutralization process | |
KR20140097492A (en) | Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation | |
CN1907862A (en) | Method of preparing nano hydroxyl zinc stannate and nano zinc stannate | |
CN102211013A (en) | Preparation method of hydrotalcite-supported gold nanocrystals and application of hydrotalcite-supported gold nanocrystals in hemoglobin adsorption | |
Liu et al. | Abalone shell-derived Mg-doped mesoporous hydroxyapatite microsphere drug delivery system loaded with icariin for inducing apoptosis of osteosarcoma cells | |
Nomicisio et al. | Layered Double Hydroxides for biomedical purposes: sustainable and green synthesis | |
Mohamed et al. | Structural features and photocatalytic behavior of titania and titania supported vanadia synthesized by polyol functionalized materials | |
Severin et al. | Sorption and cocrystallization binding of ZrIV ions with hydroxyapatite as a promising carrier of medical radionuclide 89Zr | |
Hussein-Al-Ali et al. | The in vitro therapeutic activity of ellagic acid-alginate-silver nanoparticles on breast cancer cells (MCF-7) and normal fibroblast cells (3T3) | |
Tang et al. | One-step bulk preparation of calcium carbonate nanotubes and its application in anticancer drug delivery | |
Tayama et al. | Fabrication and dual-modal imaging properties of quantum dot/silica core-shell particles with immobilized single-nanometer-sized gold nanoparticles | |
CN101905860B (en) | Hydroxyapatite hybridized nanometer crystal assembly, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131016 Termination date: 20180923 |